MedImmune Spins Drugs Into New Biotech Co., Raises $250M
AstraZeneca biologics research and development arm MedImmune LLC on Wednesday said six of its drugs will be transferred to a new independent biotechnology company that took in $250 million from a...To view the full article, register now.
Already a subscriber? Click here to view full article